Astrazeneca releases new positive meaningful results from the phase III KALOS and LOGOS trials for Breztri in patients with uncontrolled asthma

Recently full results from the positive Phase III KALOS and LOGOS trials highlighted AstraZeneca’s Breztri Aerosphere demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist medicines: Symbicort, PT009 and the Symbicort and PT009 treatment groups combined.

Note that in the pooled analysis Breztri also demonstrated clinically meaningful reductions in the annualised rate of severe asthma exacerbations versus ICS/LABA medicines in patients with or without a recent asthma exacerbation.

Alberto Papi, Professor and Chair of Respiratory Medicine at the University of Ferrara, and Director of the Respiratory Unit, CardioRespiratory Department, S. Anna University Hospital, Ferrara, Italy, and primary investigator, said: “Many of the 262 million people worldwide living with asthma remain uncontrolled and still struggle with symptoms like frequent breathlessness, coughing and wheezing despite the use of dual maintenance therapy. The KALOS and LOGOS trials show that the single fixed-dose triple therapy budesonide/glycopyrronium/formoterol, which combines the efficacy of an ICS, LAMA, and LABA, improved lung function, and, importantly, prevented future severe exacerbations in patients, regardless of exacerbation history.”

Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “With so many patients still experiencing the debilitating effects of uncontrolled asthma, we are excited about the potential for Breztri to improve lung function as well as prevent exacerbations in asthma. Building on its well-established profile in COPD, we hope to bring Breztri to patients with uncontrolled asthma as quickly as possible.”

 

---

---

Related Topics and Keywords

asthma, Astrazeneca's Breztri, BREZTRI, logos, Phase III KALOS, Phase III KALOS and LOGOS trials